In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Minerva Neurosciences, Inc. Trade Record

NASDAQ:NERV Minerva Neurosciences, Inc stock gains 16.48% Exit Sep 10, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart NERV Aug 15, 2018, priceSeries
About Minerva Neurosciences, Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The company' preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Trade Information
Trade Type
LONG
ReliabilityScore™
96.72
Entry Date
Aug 15, 2018
Entry Price
8.50
Sell Date
Sep 10, 2018
Sell Price
9.90
Net Gain
16.48%
Hold Time
17 Trading Days